Glibenclamide nanocrystals for bioavailability enhancement: Formulation design, process optimization, and pharmacodynamic evaluation

Journal of Pharmaceutical Innovation

Volumn 9, Issue 3, 2014, Pages 227-237

  Shah, Sunny R ^a   Parikh, Rajesh H ^b   Chavda, Jayant R ^a   Sheth, Navin R ^c  

^a B K Mody Government Pharmacy College   (India)

^b CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^c SAURASHTRA UNIVERSITY   (India)

Author keywords

Bioavailability enhancement; Glibenclamide; Nanocrystals; Wet milling

Indexed keywords

GLIBENCLAMIDE; NANOCRYSTAL; ZIRCONIUM OXIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84908356041     PISSN: 18725120     EISSN: 19398042     Source Type: Journal    
DOI: 10.1007/s12247-014-9189-y     Document Type: Article

References (23)

1. Seedher N, Kanojia M. Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharm Dev Technol. 2009;14(2):185-92.
2. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-78. (Pubitemid 39037234)
3. Otoom S, Hasan M, Najib N. The bioavailability of glyburide (glibenclamide) under fasting and feeding conditions: a comparative study. Int J Pharm Med. 2001;15:117-20. (Pubitemid 32730581)
4. Hardman JG, Limbird LE, editors. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. 10th ed. McGraw Hill: The Pharmacological Basis of Therapeutics; 2001.
5. Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm. 2010;402:213-20.
6. Kumar MP, Rao YM, Apte S. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr Nanosci. 2007;3:191-4. (Pubitemid 46845726)
7. Mou D, Chen H, Wan J, Huibi X, Yang X. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm. 2011;413:237-44.
8. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409:260-8.
9. Liversidge EM, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63:427-40.
10. Bachhav Y, Patravale V. SMEDDS of glyburide: formulation, in vitro evaluation, and stability studies. AAPS PharmSciTech. 2009;10(2):482-7.
11. Singh S, Verma P, Razdan B. Glibenclamide-loaded self-nanoemulsifying drug delivery system: development and characterization. Drug Dev Ind Pharm. 2010;36(8):933-45.
12. Singh S, Srinivasan K, Gowthamarajan K, Singare D, Prakash D, Gaikwad N. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm. 2011;78(3):441-6.
13. Shah SR, Parikh RH, Chavda JR, Sheth NR. Application of Plackett - Burman screening design for preparing glibenclamide nanoparticles for dissolution enhancement. Powder Technol. 2013;235:405-11.
14. Yang JZ, Young AL, Chiang P-C, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci. 2008;97(11):4869-78.
15. Dabhi MR, Limbani MD, Sheth NR. Preparation and in vivo evaluation of self-nanoemulsifying drug delivery system(Snedds) containing ezetimibe. Curr Nanosci. 2011;7:616-27.
16. Pardeike J, Müller RH. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm. 2010;391:322-9.
17. USFDA, Guidelines. USFDA. http://www.accessdata.fda.gov/scripts/cder/ dissolution/dsp-SearchResults-Dissolutions.cfm. Accessed 13 Jan 2009.
18. Prabu AK, Kumarappan C, Christudas S, Kalaichelvan V. Effect of Biophytum sensitivum on streptozotocin and nicotinamide induced diabetic rats. Asian Pac J Trop Biomed. 2012;2:31-5.
19. Verma S, Kumara S, Gokhale R, Burgess D. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 2010;406(1-2):145-52.
20. Eerdenbrugh BV, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64-75.
21. Verma S, Huey BD, Burgess D. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir. 2009;25(21):12481-7.
22. Kumar MP, Rao YM, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci. 2008;4:53-8. (Pubitemid 351513461)
23. Itoh K, Pongpeerapat A, Tozuka Y, Oguchi T, Yamamoto K. Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS. Chem Pharm Bull. 2003;51(2):171-4. (Pubitemid 41701987)